, Volume 90, Issue 4, pp 441-446
Date: 05 Oct 2010

Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

This study aims to report resource utilisation and annual cost for chronic immune thrombocytopenia (ITP) patients enrolled consecutively and followed for 1 year. A single-centre, single-arm, retrospective 1-year observational cohort study of adult patients with chronic ITP from a French hospital was conducted. Healthcare resource utilisation and mean cost per patient (with 95% confidence intervals) were estimated for the whole group. Patients requiring at least one hospitalisation formed subgroup 1. Patients with the most severe category of disease formed subgroup 2 [defined as hospitalised patients with ≥1 immunoglobulin (IVIg) infusion (usually reserved for those with bleeding score >8)]. Fifty-seven patients (42F/15M) with a mean age of 48 years (SD = 19) at ITP diagnosis were studied. Mean platelet count at diagnosis was \( {28}\pm {26} \times {1}{0^9}/{\hbox{L}} \) . Mean duration of ITP was 3.1 years (SD = 2); eight patients had undergone splenectomy at baseline. Subgroup 1 included 27 patients who were hospitalised (full hospitalisation, n = 23; and/or day hospitalisation, n = 8). Of those, 12 patients received at least one IVIg infusion during hospitalisation (subgroup 2). Total mean cost per patient for the 1-year study period was €7,293 (95% CI = 3,369–13,584) for the whole group, €15,334 (95% CI = 7,876–27,459) for subgroup 1 and €26,581 (95% CI = 12,241–50,578) for subgroup 2. IVIg accounted for 33% of costs for subgroup 1 and up to 43% of costs for patients with more severe disease (subgroup 2). Management of adults with chronic ITP is costly in France, especially for patients with severe disease. IVIg use was a major cost driver.